Mia's Feed
Medical News & Research

Apitegromab Shows Promise in Enhancing Motor Function in Spinal Muscular Atrophy Patients

Apitegromab Shows Promise in Enhancing Motor Function in Spinal Muscular Atrophy Patients

Share this article

New clinical trial results reveal that apitegromab significantly enhances motor function in patients with nonambulatory spinal muscular atrophy, offering hope for better treatment options.

2 min read

Recent research published in the Lancet Neurology highlights the potential of apitegromab, a monoclonal antibody that inhibits myostatin activation, in improving motor function among patients with nonambulatory type 2 or type 3 spinal muscular atrophy (SMA). SMA is a genetic disorder characterized by progressive muscle weakness and degeneration, affecting motor skills and mobility.

In a phase 3 clinical trial conducted at 48 hospitals, researchers evaluated the safety and effectiveness of apitegromab in young patients aged 2 to 21 years who were already receiving standard treatments like nusinersen or risdiplam. The study enrolled 188 patients, with 128 receiving apitegromab and 60 receiving a placebo, administered every four weeks.

Results demonstrated that children aged 2 to 12 years treated with apitegromab experienced a significant improvement in motor function, measured by the Hammersmith Functional Motor Scale-Expanded (HFMSE), with a mean increase of 1.8 points from baseline over 12 months compared to placebo. The 20 mg/kg dosage showed a mean difference of 1.4 points, indicating a positive trend toward motor skill enhancement. Notably, the drug was well tolerated, with adverse events comparable to those seen in the placebo group, aligning with the typical safety profile for SMA therapies.

Dr. Thomas O. Crawford of Johns Hopkins Medicine and his colleagues concluded that apitegromab is effective in improving motor capabilities and is generally safe for patients with nonambulatory SMA. These findings support the potential use of muscle-targeting therapies to mitigate motor impairment in SMA patients. For more detailed information, refer to the full study in "The Lancet Neurology".

source: https://medicalxpress.com/news/2025-08-apitegromab-motor-function-spinal-muscular.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Brain's Central Switchboard: Neurons Function as Precise Movement 'Brakes'

New research uncovers how neurons in the brain's basal ganglia act as precise control switches, enabling fine-tuned movement regulation. This breakthrough enhances understanding of motor control and offers insights for treating disorders like Parkinson's disease.

New Hampshire Becomes First State Mandating Sterilization Requests Be Honored by Medical Professionals

New Hampshire has become the first U.S. state to mandate that doctors perform sterilizations upon patient request, emphasizing reproductive rights and autonomy amidst evolving reproductive legislation.

Probiotics May Reduce Chemotherapy Side Effects in Breast Cancer Patients

Emerging research suggests that multi-strain probiotics may help reduce common chemotherapy side effects such as fatigue and nausea in breast cancer patients, improving quality of life during treatment.

Could Caffeine Play a Role in Preventing Sudden Infant Death Syndrome?

Research suggests caffeine might help prevent Sudden Infant Death Syndrome by counteracting low oxygen episodes in infants. This innovative hypothesis could open new pathways for prevention strategies in infant health.